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background: The best anticoagulation regimen for primary percutaneous coronary intervention (PCI) remains controversial. We performed 
a meta-analysis of recent trials to compare the use of bivalirudin and heparin for primary PCI.
methods: Scientific databases and websites were searched for randomized trials. The primary efficacy and safety outcomes were the 
30-day incidence of major adverse cardiac events (MACE) and major bleeding, respectively. We calculated the pooled risk ratios using 
random-effects models. Moderator analyses were used to examine the impact of routine use of glycoprotein IIb/IIIa inhibitors (GPI), radial 
access, and P2Y12 inhibitors on safety outcomes.
results: We included data from 5 trials involving 10350 patients. There was no difference in the MACE risk with bivalirudin use compared 
with heparin use (risk ratio: 1.08, 95% CI: 0.91-1.27; p=0.35). Bivalirudin use lowered the risk of major bleeding (0.64, 0.42-97; p<0.036), 
but bleeding risk varied depending on routine GPI use (0.46, 0.26-0.74) vs. bailout use (0.74, 0.44-1.23), prasugrel/ticagrelor (1.16, 0.83-
1.61) vs. clopidogrel use (0.56, 0.44-0.71), and radial access (0.59, 0.29-1.20)
Conclusion:  In primary PCI, compared to heparin use, bivalirudin use reduces the major bleeding risk and yields similar MACE incidence. 
However, the reduction in bleeding with bivalirudin can be negated by concurrently administering of prasugrel/ticagrelor with bivalirudin, 
using radial access, and avoiding routine GPI use.
 
